Perspectives

Glucagon-like peptide-1 receptor agonists – practical use in type 2 diabetes

Perspectives

Glucagon-like peptide-1 receptor agonists – practical use in type 2 diabetes

Yeung-Ae Park, Christopher J. Yates, RAHUL D. BARMANRAY

Figures

© RFBSIP/STOCK.ADOBE.COM MODEL USED FOR ILLUSTRATIVE PURPOSES ONLY
© RFBSIP/STOCK.ADOBE.COM MODEL USED FOR ILLUSTRATIVE PURPOSES ONLY

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are being increasingly prescribed for people with type 2 diabetes. They have been practice-changing owing to their glycaemic, cardiovascular, renal and weight loss benefits, and decreases in all-cause mortality. However, counselling is crucial to advise patients of safe injection techniques and common adverse events such as nausea, which may lead to cessation and avoidance of this therapeutic class. A four-phase approach to selecting, counselling and following up patients can help GPs to prescribe GLP-1RAs safely and effectively.

Key Points

  • Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have multiple glycaemic and nonglycaemic benefits in patients with type 2 diabetes, including reduced glycaemia, mortality, cardiovascular events and weight.
  • GLP-1RAs should be considered as second-line therapy in people with type 2 diabetes, especially those with established atherosclerotic cardiovascular disease.
  • Effective counselling on injection technique, dose titration and adverse effects can improve adherence to this therapeutic class.
  • Prompt follow up can identify adverse effects early and enable decisive management.